Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haoxi Health Technology (HAO) Cash & Equivalents (2023 - 2025)

Haoxi Health Technology's Cash & Equivalents history spans 3 years, with the latest figure at $6.8 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 2.18% to $6.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, up 2.18% year-over-year, with the annual reading at $8.6 million for FY2025, 29.49% up from the prior year.
  • Cash & Equivalents came in at $6.8 million for Q4 2025, down from $8.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $8.6 million in Q2 2025 to a low of $1.2 million in Q2 2023.
  • The 3-year median for Cash & Equivalents is $6.7 million (2024), against an average of $5.2 million.
  • Year-over-year, Cash & Equivalents soared 453.17% in 2024 and then increased 2.18% in 2025.
  • Haoxi Health Technology's Cash & Equivalents stood at $1.2 million in 2023, then skyrocketed by 453.17% to $6.7 million in 2024, then increased by 2.18% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for HAO's Cash & Equivalents are $6.8 million (Q4 2025), $8.6 million (Q2 2025), and $6.7 million (Q4 2024).